Successful salvage chemotherapy with amrubicin for invasive thymoma associated with myasthenia gravis.

Abstract

Anthracycline-based regimens with cisplatin have been commonly used for inoperable and relapsed thymoma. However, little information is available regarding the usefulness of salvage chemotherapy. Here, we describe a case of invasive thymoma associated with myasthenia gravis that showed a marked response to third-line chemotherapy, with single-agent amrubicin, a synthetic anthracycline analog and potent deoxyribonucleic acid topoisomerase II inhibitor. Amrubicin appears to have significant activity against invasive thymoma.

• Authors: Toshirou Fukushima, Daisuke Gomi, Takashi Kobayashi, Nodoka Sekiguchi, Akiyuki Sakamoto, Shigeru Sasaki, Tomonobu Koizumi
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 44 Issue 11 Pg. 1120-2 (Nov 2014) ISSN: 1465-3621 [Electronic] England
• PMID: 25240023 (Publication Type: Case Reports, Journal Article)
• Copyright: © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected].

Chemical References

• Anthracyclines
• Antibiotics, Antineoplastic
• amrubicin

Topics

• Adult
• Anthracyclines (therapeutic use)
• Antibiotics, Antineoplastic (therapeutic use)
• Female
• Humans
• Myasthenia Gravis (complications)
• Salvage Therapy (methods)
• Thymoma (diagnostic imaging, drug therapy, etiology, pathology)
• Thymus Neoplasms (diagnostic imaging, drug therapy, etiology, pathology)
• Tomography, X-Ray Computed
• Treatment Outcome